At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMVT Immunovant, Inc.
Market Closed 02-14 16:00:00 EST
20.33
+0.47
+2.37%
盘后20.33
+0.000.00%
18:25 EST
High20.49
Low19.89
Vol1.24M
Open19.99
D1 Closing19.86
Amplitude3.02%
Mkt Cap3.45B
Tradable Cap1.79B
Total Shares169.86M
T/O25.09M
T/O Rate1.41%
Tradable Shares88.16M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
Immunovant Q3 2025 GAAP EPS $(0.76), Inline, Pro Forma Cash Balance Of Approximately $825M As Of December 31, 2024, Including Approximately $450M Gross Proceeds From A Private Placement
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.